Rn624, ri624 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 226 | 間質性膀胱炎（ハンナ型） | 6 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-014597-17-SE (EUCTR) | 03/05/2010 | 28/10/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2B | Finland;Spain;Belgium;Germany;Sweden | ||
| 2 | EUCTR2009-014597-17-FI (EUCTR) | 24/03/2010 | 04/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2B | Finland;Germany;Belgium;Spain;Sweden | ||
| 3 | EUCTR2009-014597-17-DE (EUCTR) | 19/03/2010 | 03/12/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2B | Finland;Germany;Belgium;Spain;Sweden | ||
| 4 | EUCTR2009-014597-17-ES (EUCTR) | 08/02/2010 | 12/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) | Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vejiga dolorosa MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2B | Finland;Belgium;Spain;Germany;Sweden | ||
| 5 | EUCTR2009-014597-17-SK (EUCTR) | 03/02/2010 | 11/02/2010 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Slovakia;Finland;Spain;Belgium;Germany;Sweden | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2009-014597-17-BE (EUCTR) | 24/12/2009 | 09/11/2009 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 Product Name: Tanezumab Product Code: PF-04383119 INN or Proposed INN: Tanezumab Other descriptive name: RN624, RI624 | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 2B | Finland;Germany;Belgium;Spain;Sweden |